PBS listings of Dupixent (dupilumab) for uncontrolled severe asthma (1st April 2021) and severe atopic dermatitis (1st March 2021)
Dupixent (dupilumab) is now listed on the Pharmaceutical Benefits Scheme (PBS) in Australia for the treatment of patients aged 12 years and older with:
- Uncontrolled severe asthma from 1st April 2021; and
- Severe atopic dermatitis who have failed to respond to optimally prescribed topical treatments from 1st March 2021.
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. IL-4 and IL-13 are key and central drivers of type 2 inflammation that plays a central role in allergic and eosinophilic asthma, as well as atopic dermatitis. Dupixent is not an immunosuppressant.
Dupixent is jointly developed by Sanofi and Regeneron under a global collaboration agreement.
Full Product Information is available from Sanofi-Aventis Australia Pty Ltd at www.guildlink.com.au/gc/ws/sw/pi.cfm?product=swpdupix or by contacting 1800 818 806.
Consumer Medicine Information (CMI) is available at www.guildlink.com.au/gc/ws/sw/cmi.cfm?product=swcdupix
Further information is available here: